nodes	percent_of_prediction	percent_of_DWPC	metapath
Ruxolitinib—BMPR2—artery—atherosclerosis	0.00882	0.0346	CbGeAlD
Ruxolitinib—BMPR2—blood vessel—atherosclerosis	0.00687	0.027	CbGeAlD
Ruxolitinib—PRKG2—cardiovascular system—atherosclerosis	0.00638	0.025	CbGeAlD
Ruxolitinib—RPS6KA6—cardiovascular system—atherosclerosis	0.00572	0.0224	CbGeAlD
Ruxolitinib—PRKCE—adipose tissue—atherosclerosis	0.00525	0.0206	CbGeAlD
Ruxolitinib—Herpes zoster—Niacin—atherosclerosis	0.00518	0.0405	CcSEcCtD
Ruxolitinib—JAK2—blood vessel—atherosclerosis	0.00494	0.0194	CbGeAlD
Ruxolitinib—PLK3—cardiovascular system—atherosclerosis	0.00478	0.0187	CbGeAlD
Ruxolitinib—JAK3—connective tissue—atherosclerosis	0.00424	0.0166	CbGeAlD
Ruxolitinib—PLK3—adipose tissue—atherosclerosis	0.00421	0.0165	CbGeAlD
Ruxolitinib—JAK1—connective tissue—atherosclerosis	0.00421	0.0165	CbGeAlD
Ruxolitinib—PRKG2—liver—atherosclerosis	0.00395	0.0155	CbGeAlD
Ruxolitinib—CAMK1—adipose tissue—atherosclerosis	0.00394	0.0155	CbGeAlD
Ruxolitinib—HIPK2—connective tissue—atherosclerosis	0.00393	0.0154	CbGeAlD
Ruxolitinib—MARK2—adipose tissue—atherosclerosis	0.00383	0.015	CbGeAlD
Ruxolitinib—PRKCE—liver—atherosclerosis	0.00368	0.0144	CbGeAlD
Ruxolitinib—JAK1—cardiovascular system—atherosclerosis	0.00367	0.0144	CbGeAlD
Ruxolitinib—ROCK1—connective tissue—atherosclerosis	0.00363	0.0142	CbGeAlD
Ruxolitinib—PLK1—liver—atherosclerosis	0.00354	0.0139	CbGeAlD
Ruxolitinib—RPS6KA6—liver—atherosclerosis	0.00354	0.0139	CbGeAlD
Ruxolitinib—TAOK2—adipose tissue—atherosclerosis	0.00354	0.0139	CbGeAlD
Ruxolitinib—BMPR2—connective tissue—atherosclerosis	0.00352	0.0138	CbGeAlD
Ruxolitinib—PLK1—Fluvastatin—Rosuvastatin—atherosclerosis	0.00348	0.268	CbGdCrCtD
Ruxolitinib—HIPK2—cardiovascular system—atherosclerosis	0.00342	0.0134	CbGeAlD
Ruxolitinib—PLK1—Simvastatin—Lovastatin—atherosclerosis	0.00333	0.256	CbGdCrCtD
Ruxolitinib—PLK1—Simvastatin—Pravastatin—atherosclerosis	0.00333	0.256	CbGdCrCtD
Ruxolitinib—DAPK3—cardiovascular system—atherosclerosis	0.00329	0.0129	CbGeAlD
Ruxolitinib—JAK3—adipose tissue—atherosclerosis	0.00325	0.0128	CbGeAlD
Ruxolitinib—JAK1—adipose tissue—atherosclerosis	0.00323	0.0127	CbGeAlD
Ruxolitinib—DCLK1—adipose tissue—atherosclerosis	0.00323	0.0127	CbGeAlD
Ruxolitinib—ROCK1—cardiovascular system—atherosclerosis	0.00316	0.0124	CbGeAlD
Ruxolitinib—CAMK1D—adipose tissue—atherosclerosis	0.00315	0.0124	CbGeAlD
Ruxolitinib—BMP2K—connective tissue—atherosclerosis	0.00315	0.0124	CbGeAlD
Ruxolitinib—PHKG2—adipose tissue—atherosclerosis	0.00314	0.0123	CbGeAlD
Ruxolitinib—DAPK2—adipose tissue—atherosclerosis	0.00308	0.0121	CbGeAlD
Ruxolitinib—DYRK1A—cardiovascular system—atherosclerosis	0.00308	0.0121	CbGeAlD
Ruxolitinib—BMPR2—cardiovascular system—atherosclerosis	0.00307	0.012	CbGeAlD
Ruxolitinib—STK16—adipose tissue—atherosclerosis	0.00303	0.0119	CbGeAlD
Ruxolitinib—HIPK2—adipose tissue—atherosclerosis	0.00302	0.0118	CbGeAlD
Ruxolitinib—PLK3—liver—atherosclerosis	0.00295	0.0116	CbGeAlD
Ruxolitinib—Urinary tract infection—Rosuvastatin—atherosclerosis	0.00292	0.0228	CcSEcCtD
Ruxolitinib—DAPK3—adipose tissue—atherosclerosis	0.0029	0.0114	CbGeAlD
Ruxolitinib—CLK2—adipose tissue—atherosclerosis	0.00287	0.0113	CbGeAlD
Ruxolitinib—MAP3K2—connective tissue—atherosclerosis	0.00286	0.0112	CbGeAlD
Ruxolitinib—Haematuria—Rosuvastatin—atherosclerosis	0.00286	0.0223	CcSEcCtD
Ruxolitinib—Alanine aminotransferase increased—Ezetimibe—atherosclerosis	0.00285	0.0223	CcSEcCtD
Ruxolitinib—PLK1—Pitavastatin—Rosuvastatin—atherosclerosis	0.00284	0.219	CbGdCrCtD
Ruxolitinib—Hepatobiliary disease—Rosuvastatin—atherosclerosis	0.00284	0.0222	CcSEcCtD
Ruxolitinib—Gastrointestinal haemorrhage—Niacin—atherosclerosis	0.00283	0.0221	CcSEcCtD
Ruxolitinib—TYK2—connective tissue—atherosclerosis	0.00279	0.0109	CbGeAlD
Ruxolitinib—CAMK1—liver—atherosclerosis	0.00276	0.0108	CbGeAlD
Ruxolitinib—MKNK2—connective tissue—atherosclerosis	0.00275	0.0108	CbGeAlD
Ruxolitinib—CAMK2G—cardiovascular system—atherosclerosis	0.00274	0.0108	CbGeAlD
Ruxolitinib—DYRK1A—adipose tissue—atherosclerosis	0.00271	0.0106	CbGeAlD
Ruxolitinib—BMPR2—adipose tissue—atherosclerosis	0.0027	0.0106	CbGeAlD
Ruxolitinib—RET—connective tissue—atherosclerosis	0.00268	0.0105	CbGeAlD
Ruxolitinib—NUAK2—adipose tissue—atherosclerosis	0.00258	0.0101	CbGeAlD
Ruxolitinib—JAK2—connective tissue—atherosclerosis	0.00253	0.00994	CbGeAlD
Ruxolitinib—Infestation—Ezetimibe—atherosclerosis	0.00249	0.0195	CcSEcCtD
Ruxolitinib—Infestation NOS—Ezetimibe—atherosclerosis	0.00249	0.0195	CcSEcCtD
Ruxolitinib—TAOK2—liver—atherosclerosis	0.00248	0.00973	CbGeAlD
Ruxolitinib—Urinary tract infection—Lovastatin—atherosclerosis	0.00247	0.0193	CcSEcCtD
Ruxolitinib—Alanine aminotransferase increased—Pravastatin—atherosclerosis	0.00246	0.0192	CcSEcCtD
Ruxolitinib—TYK2—cardiovascular system—atherosclerosis	0.00242	0.0095	CbGeAlD
Ruxolitinib—CAMK2G—adipose tissue—atherosclerosis	0.00242	0.00949	CbGeAlD
Ruxolitinib—BMP2K—adipose tissue—atherosclerosis	0.00242	0.00949	CbGeAlD
Ruxolitinib—LRRK2—adipose tissue—atherosclerosis	0.0024	0.0094	CbGeAlD
Ruxolitinib—MKNK2—cardiovascular system—atherosclerosis	0.00239	0.00938	CbGeAlD
Ruxolitinib—Hepatobiliary disease—Ezetimibe—atherosclerosis	0.00236	0.0184	CcSEcCtD
Ruxolitinib—Flatulence—Rosuvastatin—atherosclerosis	0.00231	0.018	CcSEcCtD
Ruxolitinib—JAK1—liver—atherosclerosis	0.00227	0.00889	CbGeAlD
Ruxolitinib—TAOK3—connective tissue—atherosclerosis	0.00223	0.00873	CbGeAlD
Ruxolitinib—CAMK1D—liver—atherosclerosis	0.00221	0.00868	CbGeAlD
Ruxolitinib—JAK2—cardiovascular system—atherosclerosis	0.00221	0.00865	CbGeAlD
Ruxolitinib—PHKG2—liver—atherosclerosis	0.0022	0.00863	CbGeAlD
Ruxolitinib—MAP3K2—adipose tissue—atherosclerosis	0.0022	0.00862	CbGeAlD
Ruxolitinib—Weight increased—Pravastatin—atherosclerosis	0.00219	0.0171	CcSEcCtD
Ruxolitinib—Weight decreased—Pravastatin—atherosclerosis	0.00218	0.017	CcSEcCtD
Ruxolitinib—MAP3K7—adipose tissue—atherosclerosis	0.00218	0.00854	CbGeAlD
Ruxolitinib—TYK2—adipose tissue—atherosclerosis	0.00214	0.00838	CbGeAlD
Ruxolitinib—STK16—liver—atherosclerosis	0.00213	0.00834	CbGeAlD
Ruxolitinib—MAP3K3—cardiovascular system—atherosclerosis	0.00213	0.00833	CbGeAlD
Ruxolitinib—HIPK2—liver—atherosclerosis	0.00212	0.0083	CbGeAlD
Ruxolitinib—IRAK1—adipose tissue—atherosclerosis	0.00211	0.00827	CbGeAlD
Ruxolitinib—MKNK2—adipose tissue—atherosclerosis	0.00211	0.00827	CbGeAlD
Ruxolitinib—Urinary tract infection—Pravastatin—atherosclerosis	0.00209	0.0163	CcSEcCtD
Ruxolitinib—DAPK3—liver—atherosclerosis	0.00203	0.00797	CbGeAlD
Ruxolitinib—CLK2—liver—atherosclerosis	0.00201	0.0079	CbGeAlD
Ruxolitinib—Haemoglobin—Niacin—atherosclerosis	0.00197	0.0154	CcSEcCtD
Ruxolitinib—Haemorrhage—Niacin—atherosclerosis	0.00196	0.0153	CcSEcCtD
Ruxolitinib—Flatulence—Lovastatin—atherosclerosis	0.00196	0.0153	CcSEcCtD
Ruxolitinib—ROCK1—liver—atherosclerosis	0.00195	0.00765	CbGeAlD
Ruxolitinib—Malnutrition—Ezetimibe—atherosclerosis	0.00195	0.0152	CcSEcCtD
Ruxolitinib—JAK2—adipose tissue—atherosclerosis	0.00194	0.00763	CbGeAlD
Ruxolitinib—TAOK3—cardiovascular system—atherosclerosis	0.00194	0.0076	CbGeAlD
Ruxolitinib—Flatulence—Ezetimibe—atherosclerosis	0.00192	0.015	CcSEcCtD
Ruxolitinib—DYRK1A—liver—atherosclerosis	0.0019	0.00747	CbGeAlD
Ruxolitinib—Infection—Rosuvastatin—atherosclerosis	0.0019	0.0148	CcSEcCtD
Ruxolitinib—BMPR2—liver—atherosclerosis	0.0019	0.00744	CbGeAlD
Ruxolitinib—Nervous system disorder—Rosuvastatin—atherosclerosis	0.00188	0.0147	CcSEcCtD
Ruxolitinib—MAP3K3—adipose tissue—atherosclerosis	0.00187	0.00735	CbGeAlD
Ruxolitinib—Thrombocytopenia—Rosuvastatin—atherosclerosis	0.00187	0.0146	CcSEcCtD
Ruxolitinib—Flatulence—Simvastatin—atherosclerosis	0.00183	0.0143	CcSEcCtD
Ruxolitinib—NUAK2—liver—atherosclerosis	0.00181	0.00711	CbGeAlD
Ruxolitinib—Anaemia—Ezetimibe—atherosclerosis	0.0018	0.0141	CcSEcCtD
Ruxolitinib—Anaemia—Simvastatin—atherosclerosis	0.00172	0.0134	CcSEcCtD
Ruxolitinib—TAOK3—adipose tissue—atherosclerosis	0.00171	0.0067	CbGeAlD
Ruxolitinib—Malnutrition—Niacin—atherosclerosis	0.00171	0.0133	CcSEcCtD
Ruxolitinib—CAMK2G—liver—atherosclerosis	0.0017	0.00665	CbGeAlD
Ruxolitinib—BMP2K—liver—atherosclerosis	0.0017	0.00665	CbGeAlD
Ruxolitinib—LRRK2—liver—atherosclerosis	0.00168	0.00659	CbGeAlD
Ruxolitinib—Flatulence—Niacin—atherosclerosis	0.00168	0.0131	CcSEcCtD
Ruxolitinib—Flatulence—Pravastatin—atherosclerosis	0.00166	0.0129	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Ezetimibe—atherosclerosis	0.00165	0.0129	CcSEcCtD
Ruxolitinib—Infection—Lovastatin—atherosclerosis	0.00161	0.0126	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Lovastatin—atherosclerosis	0.00159	0.0124	CcSEcCtD
Ruxolitinib—Infection—Ezetimibe—atherosclerosis	0.00158	0.0123	CcSEcCtD
Ruxolitinib—Nervous system disorder—Ezetimibe—atherosclerosis	0.00156	0.0122	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Ezetimibe—atherosclerosis	0.00156	0.0122	CcSEcCtD
Ruxolitinib—Anaemia—Pravastatin—atherosclerosis	0.00155	0.0121	CcSEcCtD
Ruxolitinib—Skin disorder—Ezetimibe—atherosclerosis	0.00154	0.0121	CcSEcCtD
Ruxolitinib—MAP3K2—liver—atherosclerosis	0.00154	0.00604	CbGeAlD
Ruxolitinib—MAP3K7—liver—atherosclerosis	0.00153	0.00599	CbGeAlD
Ruxolitinib—Infection—Simvastatin—atherosclerosis	0.00151	0.0118	CcSEcCtD
Ruxolitinib—TYK2—liver—atherosclerosis	0.0015	0.00588	CbGeAlD
Ruxolitinib—Thrombocytopenia—Simvastatin—atherosclerosis	0.00148	0.0116	CcSEcCtD
Ruxolitinib—MKNK2—liver—atherosclerosis	0.00148	0.0058	CbGeAlD
Ruxolitinib—IRAK1—liver—atherosclerosis	0.00148	0.0058	CbGeAlD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Niacin—atherosclerosis	0.00144	0.0113	CcSEcCtD
Ruxolitinib—Fatigue—Lovastatin—atherosclerosis	0.0014	0.0109	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Ezetimibe—atherosclerosis	0.00137	0.0107	CcSEcCtD
Ruxolitinib—Asthenia—Rosuvastatin—atherosclerosis	0.00137	0.0107	CcSEcCtD
Ruxolitinib—Fatigue—Ezetimibe—atherosclerosis	0.00137	0.0107	CcSEcCtD
Ruxolitinib—JAK2—liver—atherosclerosis	0.00136	0.00535	CbGeAlD
Ruxolitinib—Infection—Pravastatin—atherosclerosis	0.00136	0.0106	CcSEcCtD
Ruxolitinib—Pruritus—Rosuvastatin—atherosclerosis	0.00135	0.0106	CcSEcCtD
Ruxolitinib—Skin disorder—Niacin—atherosclerosis	0.00135	0.0106	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Pravastatin—atherosclerosis	0.00134	0.0105	CcSEcCtD
Ruxolitinib—MAP3K3—liver—atherosclerosis	0.00131	0.00515	CbGeAlD
Ruxolitinib—Gastrointestinal disorder—Simvastatin—atherosclerosis	0.00131	0.0102	CcSEcCtD
Ruxolitinib—Fatigue—Simvastatin—atherosclerosis	0.00131	0.0102	CcSEcCtD
Ruxolitinib—Body temperature increased—Lovastatin—atherosclerosis	0.00128	0.01	CcSEcCtD
Ruxolitinib—Dizziness—Rosuvastatin—atherosclerosis	0.00127	0.00988	CcSEcCtD
Ruxolitinib—Body temperature increased—Ezetimibe—atherosclerosis	0.00126	0.00982	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Niacin—atherosclerosis	0.0012	0.00939	CcSEcCtD
Ruxolitinib—Body temperature increased—Simvastatin—atherosclerosis	0.0012	0.00936	CcSEcCtD
Ruxolitinib—Headache—Rosuvastatin—atherosclerosis	0.0012	0.00936	CcSEcCtD
Ruxolitinib—TAOK3—liver—atherosclerosis	0.0012	0.0047	CbGeAlD
Ruxolitinib—Fatigue—Pravastatin—atherosclerosis	0.00118	0.00923	CcSEcCtD
Ruxolitinib—Asthenia—Lovastatin—atherosclerosis	0.00116	0.00908	CcSEcCtD
Ruxolitinib—Pruritus—Lovastatin—atherosclerosis	0.00115	0.00896	CcSEcCtD
Ruxolitinib—Asthenia—Ezetimibe—atherosclerosis	0.00114	0.00891	CcSEcCtD
Ruxolitinib—Pruritus—Ezetimibe—atherosclerosis	0.00113	0.00879	CcSEcCtD
Ruxolitinib—Body temperature increased—Niacin—atherosclerosis	0.0011	0.0086	CcSEcCtD
Ruxolitinib—Asthenia—Simvastatin—atherosclerosis	0.00109	0.0085	CcSEcCtD
Ruxolitinib—Body temperature increased—Pravastatin—atherosclerosis	0.00108	0.00846	CcSEcCtD
Ruxolitinib—Pruritus—Simvastatin—atherosclerosis	0.00107	0.00838	CcSEcCtD
Ruxolitinib—Dizziness—Lovastatin—atherosclerosis	0.00107	0.00837	CcSEcCtD
Ruxolitinib—Dizziness—Ezetimibe—atherosclerosis	0.00105	0.00821	CcSEcCtD
Ruxolitinib—Headache—Lovastatin—atherosclerosis	0.00102	0.00793	CcSEcCtD
Ruxolitinib—Dizziness—Simvastatin—atherosclerosis	0.001	0.00783	CcSEcCtD
Ruxolitinib—Asthenia—Niacin—atherosclerosis	0.000999	0.0078	CcSEcCtD
Ruxolitinib—Headache—Ezetimibe—atherosclerosis	0.000996	0.00778	CcSEcCtD
Ruxolitinib—Pruritus—Niacin—atherosclerosis	0.000985	0.00769	CcSEcCtD
Ruxolitinib—Asthenia—Pravastatin—atherosclerosis	0.000984	0.00768	CcSEcCtD
Ruxolitinib—Pruritus—Pravastatin—atherosclerosis	0.00097	0.00758	CcSEcCtD
Ruxolitinib—Headache—Simvastatin—atherosclerosis	0.00095	0.00742	CcSEcCtD
Ruxolitinib—Dizziness—Niacin—atherosclerosis	0.000921	0.00719	CcSEcCtD
Ruxolitinib—Dizziness—Pravastatin—atherosclerosis	0.000907	0.00708	CcSEcCtD
Ruxolitinib—Headache—Niacin—atherosclerosis	0.000872	0.00681	CcSEcCtD
Ruxolitinib—Headache—Pravastatin—atherosclerosis	0.000859	0.00671	CcSEcCtD
Ruxolitinib—CYP3A4—liver—atherosclerosis	0.000364	0.00143	CbGeAlD
Ruxolitinib—BMPR2—Signaling Pathways—AKT1—atherosclerosis	1.19e-05	1.96e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—APOA1—atherosclerosis	1.18e-05	1.96e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—MAPK3—atherosclerosis	1.18e-05	1.96e-05	CbGpPWpGaD
Ruxolitinib—CAMK2G—Immune System—IL6—atherosclerosis	1.18e-05	1.96e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—IL1B—atherosclerosis	1.18e-05	1.96e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—ESR1—atherosclerosis	1.18e-05	1.95e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—MMP3—atherosclerosis	1.17e-05	1.94e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—PTGS2—atherosclerosis	1.17e-05	1.94e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—IGF2—atherosclerosis	1.17e-05	1.94e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—F2—atherosclerosis	1.16e-05	1.93e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—LEP—atherosclerosis	1.16e-05	1.92e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—APOE—atherosclerosis	1.16e-05	1.92e-05	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—IL6—atherosclerosis	1.16e-05	1.91e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Innate Immune System—IL6—atherosclerosis	1.15e-05	1.91e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—CAV1—atherosclerosis	1.15e-05	1.91e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—APOA1—atherosclerosis	1.15e-05	1.9e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—TGFB1—atherosclerosis	1.15e-05	1.9e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—IL1B—atherosclerosis	1.15e-05	1.9e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—ESR1—atherosclerosis	1.14e-05	1.89e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—MAPK3—atherosclerosis	1.14e-05	1.89e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—NFKB1—atherosclerosis	1.14e-05	1.88e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—APOB—atherosclerosis	1.13e-05	1.88e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—MMP9—atherosclerosis	1.13e-05	1.88e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—F2—atherosclerosis	1.13e-05	1.87e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Innate Immune System—AKT1—atherosclerosis	1.13e-05	1.87e-05	CbGpPWpGaD
Ruxolitinib—JAK2—GPCR downstream signaling—CXCL8—atherosclerosis	1.13e-05	1.86e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—NFKB1—atherosclerosis	1.12e-05	1.86e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—EDN1—atherosclerosis	1.12e-05	1.85e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—MAPK8—atherosclerosis	1.12e-05	1.85e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—PIK3CG—atherosclerosis	1.11e-05	1.84e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—ESR1—atherosclerosis	1.11e-05	1.84e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CCL5—atherosclerosis	1.11e-05	1.83e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—INS—atherosclerosis	1.11e-05	1.83e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—TGFB1—atherosclerosis	1.11e-05	1.83e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—MAPK8—atherosclerosis	1.1e-05	1.83e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—NFKB1—atherosclerosis	1.1e-05	1.83e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling by GPCR—AKT1—atherosclerosis	1.1e-05	1.82e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Disease—AKT1—atherosclerosis	1.1e-05	1.82e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—F2—atherosclerosis	1.1e-05	1.82e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Innate Immune System—AKT1—atherosclerosis	1.1e-05	1.81e-05	CbGpPWpGaD
Ruxolitinib—CAMK2G—Immune System—AKT1—atherosclerosis	1.09e-05	1.81e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—IL6—atherosclerosis	1.09e-05	1.8e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—MAPK8—atherosclerosis	1.08e-05	1.79e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—LPL—atherosclerosis	1.08e-05	1.79e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—PIK3CG—atherosclerosis	1.08e-05	1.79e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—CXCL8—atherosclerosis	1.08e-05	1.79e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—NFKB1—atherosclerosis	1.07e-05	1.77e-05	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—AKT1—atherosclerosis	1.07e-05	1.76e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Innate Immune System—AKT1—atherosclerosis	1.06e-05	1.76e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—CXCL8—atherosclerosis	1.06e-05	1.76e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—INS—atherosclerosis	1.05e-05	1.75e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—PRKCG—atherosclerosis	1.05e-05	1.74e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—MAPK8—atherosclerosis	1.05e-05	1.74e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—PIK3CG—atherosclerosis	1.05e-05	1.74e-05	CbGpPWpGaD
Ruxolitinib—JAK1—GPCR downstream signaling—AKT1—atherosclerosis	1.04e-05	1.73e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—CCL2—atherosclerosis	1.04e-05	1.72e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—MAPK3—atherosclerosis	1.04e-05	1.72e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—SPP1—atherosclerosis	1.03e-05	1.7e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling by GPCR—IL6—atherosclerosis	1.03e-05	1.7e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—GPCR downstream signaling—AKT1—atherosclerosis	1.03e-05	1.7e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—INS—atherosclerosis	1.02e-05	1.7e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—CXCL8—atherosclerosis	1.02e-05	1.69e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Adaptive Immune System—AKT1—atherosclerosis	1.02e-05	1.69e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—STAT3—atherosclerosis	1.02e-05	1.69e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—IGF1—atherosclerosis	1.02e-05	1.69e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Developmental Biology—IL6—atherosclerosis	1.02e-05	1.69e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—VEGFA—atherosclerosis	1.02e-05	1.69e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—SERPINE1—atherosclerosis	1.02e-05	1.69e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling by GPCR—IL6—atherosclerosis	1.01e-05	1.67e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—STAT3—atherosclerosis	1.01e-05	1.67e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—CCL2—atherosclerosis	1.01e-05	1.67e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—AKT1—atherosclerosis	1.01e-05	1.66e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—IFNG—atherosclerosis	1e-05	1.66e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—ABCG1—atherosclerosis	9.97e-06	1.65e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—INS—atherosclerosis	9.93e-06	1.64e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—STAT3—atherosclerosis	9.91e-06	1.64e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—IGF1—atherosclerosis	9.9e-06	1.64e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—CCL2—atherosclerosis	9.77e-06	1.62e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—MMP9—atherosclerosis	9.76e-06	1.62e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—MAPK3—atherosclerosis	9.75e-06	1.61e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—NOS3—atherosclerosis	9.72e-06	1.61e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—SERPINE1—atherosclerosis	9.69e-06	1.6e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—NFKB1—atherosclerosis	9.65e-06	1.6e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—MAPK3—atherosclerosis	9.63e-06	1.6e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—STAT3—atherosclerosis	9.61e-06	1.59e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—IGF1—atherosclerosis	9.61e-06	1.59e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—MMP9—atherosclerosis	9.6e-06	1.59e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—PDGFB—atherosclerosis	9.5e-06	1.57e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—NFKB1—atherosclerosis	9.5e-06	1.57e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—MAPK8—atherosclerosis	9.49e-06	1.57e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—MAPK3—atherosclerosis	9.46e-06	1.57e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling by GPCR—AKT1—atherosclerosis	9.46e-06	1.57e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Developmental Biology—AKT1—atherosclerosis	9.4e-06	1.56e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—SERPINE1—atherosclerosis	9.4e-06	1.56e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—IL6—atherosclerosis	9.37e-06	1.55e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—FABP4—atherosclerosis	9.37e-06	1.55e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—LCAT—atherosclerosis	9.37e-06	1.55e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—TGFB1—atherosclerosis	9.35e-06	1.55e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—MAPK8—atherosclerosis	9.33e-06	1.55e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling by GPCR—AKT1—atherosclerosis	9.31e-06	1.54e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—AGT—atherosclerosis	9.27e-06	1.53e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—NOS3—atherosclerosis	9.25e-06	1.53e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Hemostasis—AKT1—atherosclerosis	9.23e-06	1.53e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—APOA4—atherosclerosis	9.2e-06	1.52e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—MAPK3—atherosclerosis	9.18e-06	1.52e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—STAT3—atherosclerosis	9.15e-06	1.51e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—SERPINE1—atherosclerosis	9.12e-06	1.51e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—APOE—atherosclerosis	9.08e-06	1.5e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—LEP—atherosclerosis	9.08e-06	1.5e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—CYP7A1—atherosclerosis	9.04e-06	1.5e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—IL6—atherosclerosis	9e-06	1.49e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CAV1—atherosclerosis	9e-06	1.49e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—APOA1—atherosclerosis	8.98e-06	1.49e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—NOS3—atherosclerosis	8.98e-06	1.49e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—IL1B—atherosclerosis	8.96e-06	1.48e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—PTGS2—atherosclerosis	8.89e-06	1.47e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—VEGFA—atherosclerosis	8.76e-06	1.45e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—MAPK3—atherosclerosis	8.74e-06	1.45e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—NOS3—atherosclerosis	8.71e-06	1.44e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—STAT3—atherosclerosis	8.68e-06	1.44e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—ESR1—atherosclerosis	8.67e-06	1.44e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—IL6—atherosclerosis	8.65e-06	1.43e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—AKT1—atherosclerosis	8.65e-06	1.43e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—VEGFA—atherosclerosis	8.62e-06	1.43e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—F2—atherosclerosis	8.57e-06	1.42e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—STAT3—atherosclerosis	8.53e-06	1.41e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—TGFB1—atherosclerosis	8.48e-06	1.4e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—NFKB1—atherosclerosis	8.35e-06	1.38e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—CYP27A1—atherosclerosis	8.35e-06	1.38e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—IL6—atherosclerosis	8.35e-06	1.38e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—AKT1—atherosclerosis	8.31e-06	1.38e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—MAPK3—atherosclerosis	8.29e-06	1.37e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—MAPK8—atherosclerosis	8.21e-06	1.36e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—CXCL8—atherosclerosis	8.2e-06	1.36e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—PIK3CG—atherosclerosis	8.2e-06	1.36e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—MAPK3—atherosclerosis	8.15e-06	1.35e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—TGFB1—atherosclerosis	8.04e-06	1.33e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—AKT1—atherosclerosis	7.98e-06	1.32e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—CXCL8—atherosclerosis	7.96e-06	1.32e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—ALOX5AP—atherosclerosis	7.92e-06	1.31e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—ALOX15—atherosclerosis	7.92e-06	1.31e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—APOA2—atherosclerosis	7.92e-06	1.31e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PLA2G2A—atherosclerosis	7.92e-06	1.31e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—TGFB1—atherosclerosis	7.91e-06	1.31e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—MAPK3—atherosclerosis	7.85e-06	1.3e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—ABCG5—atherosclerosis	7.82e-06	1.3e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—INS—atherosclerosis	7.76e-06	1.28e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—CXCL8—atherosclerosis	7.72e-06	1.28e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—AKT1—atherosclerosis	7.7e-06	1.27e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CCL2—atherosclerosis	7.63e-06	1.26e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—IL6—atherosclerosis	7.57e-06	1.25e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—LPA—atherosclerosis	7.55e-06	1.25e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—STAT3—atherosclerosis	7.51e-06	1.24e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—IGF1—atherosclerosis	7.51e-06	1.24e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—MMP9—atherosclerosis	7.42e-06	1.23e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—NFKB1—atherosclerosis	7.34e-06	1.22e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—BGN—atherosclerosis	7.32e-06	1.21e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—APOA5—atherosclerosis	7.24e-06	1.2e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—MAPK8—atherosclerosis	7.22e-06	1.19e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—MMP9—atherosclerosis	7.2e-06	1.19e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—MAPK3—atherosclerosis	7.17e-06	1.19e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—IL6—atherosclerosis	7.13e-06	1.18e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—SERPINE1—atherosclerosis	7.13e-06	1.18e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—NFKB1—atherosclerosis	7.13e-06	1.18e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—IL6—atherosclerosis	7.04e-06	1.17e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—MAPK8—atherosclerosis	7.01e-06	1.16e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—MMP9—atherosclerosis	6.99e-06	1.16e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—AKT1—atherosclerosis	6.99e-06	1.16e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PLA2G1B—atherosclerosis	6.97e-06	1.15e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—STAT3—atherosclerosis	6.93e-06	1.15e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—IL6—atherosclerosis	6.92e-06	1.15e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—NFKB1—atherosclerosis	6.91e-06	1.14e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—NOS3—atherosclerosis	6.8e-06	1.13e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—MAPK8—atherosclerosis	6.79e-06	1.13e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—ALOX5—atherosclerosis	6.73e-06	1.11e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—IL6—atherosclerosis	6.71e-06	1.11e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—VEGFA—atherosclerosis	6.66e-06	1.1e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—MAPK3—atherosclerosis	6.62e-06	1.1e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—STAT3—atherosclerosis	6.6e-06	1.09e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—AKT1—atherosclerosis	6.58e-06	1.09e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—AKT1—atherosclerosis	6.5e-06	1.08e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—VEGFA—atherosclerosis	6.47e-06	1.07e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—TGFB1—atherosclerosis	6.43e-06	1.06e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—STAT3—atherosclerosis	6.4e-06	1.06e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—IL6—atherosclerosis	6.39e-06	1.06e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—AKT1—atherosclerosis	6.38e-06	1.06e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—MAPK3—atherosclerosis	6.3e-06	1.04e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—VEGFA—atherosclerosis	6.27e-06	1.04e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—STAT3—atherosclerosis	6.21e-06	1.03e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—AKT1—atherosclerosis	6.19e-06	1.03e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—MAPK3—atherosclerosis	6.12e-06	1.01e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—TGFB1—atherosclerosis	6.12e-06	1.01e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—IL6—atherosclerosis	6.06e-06	1e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—NAMPT—atherosclerosis	6.04e-06	1e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CXCL8—atherosclerosis	6.04e-06	9.99e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—LIPC—atherosclerosis	6e-06	9.94e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—APOC3—atherosclerosis	5.96e-06	9.88e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—IL6—atherosclerosis	5.96e-06	9.87e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—TGFB1—atherosclerosis	5.94e-06	9.83e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—MAPK3—atherosclerosis	5.93e-06	9.83e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—LDLR—atherosclerosis	5.93e-06	9.82e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—AKT1—atherosclerosis	5.89e-06	9.76e-06	CbGpPWpGaD
Ruxolitinib—JAK2—GPCR downstream signaling—AKT1—atherosclerosis	5.83e-06	9.65e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—CETP—atherosclerosis	5.79e-06	9.59e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—TGFB1—atherosclerosis	5.76e-06	9.53e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—IL6—atherosclerosis	5.74e-06	9.5e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—AKT1—atherosclerosis	5.59e-06	9.26e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—SCARB1—atherosclerosis	5.55e-06	9.18e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—AKT1—atherosclerosis	5.5e-06	9.1e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—MMP9—atherosclerosis	5.46e-06	9.04e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—NFKB1—atherosclerosis	5.4e-06	8.94e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—MAPK8—atherosclerosis	5.31e-06	8.79e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—AKT1—atherosclerosis	5.29e-06	8.77e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—IL6—atherosclerosis	5.24e-06	8.68e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—HMGCR—atherosclerosis	5.24e-06	8.67e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—VEGFA—atherosclerosis	4.9e-06	8.12e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—STAT3—atherosclerosis	4.85e-06	8.04e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—IL6—atherosclerosis	4.84e-06	8.02e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—AKT1—atherosclerosis	4.84e-06	8.01e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—ABCA1—atherosclerosis	4.67e-06	7.73e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—MAPK3—atherosclerosis	4.64e-06	7.68e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—IL6—atherosclerosis	4.61e-06	7.63e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—TGFB1—atherosclerosis	4.5e-06	7.45e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—IL6—atherosclerosis	4.47e-06	7.41e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—AKT1—atherosclerosis	4.47e-06	7.4e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—IL6—atherosclerosis	4.34e-06	7.18e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—AKT1—atherosclerosis	4.25e-06	7.04e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—AKT1—atherosclerosis	4.13e-06	6.83e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—HMOX1—atherosclerosis	4e-06	6.63e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—AKT1—atherosclerosis	4e-06	6.63e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—APOB—atherosclerosis	3.84e-06	6.35e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—GSTM1—atherosclerosis	3.73e-06	6.18e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—LPL—atherosclerosis	3.66e-06	6.06e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—GPX1—atherosclerosis	3.57e-06	5.92e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—CD36—atherosclerosis	3.48e-06	5.76e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—IL6—atherosclerosis	3.39e-06	5.61e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—MTHFR—atherosclerosis	3.3e-06	5.46e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PPARA—atherosclerosis	3.24e-06	5.36e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—AGT—atherosclerosis	3.13e-06	5.19e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—AKT1—atherosclerosis	3.13e-06	5.18e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—APOE—atherosclerosis	3.07e-06	5.08e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—CAV1—atherosclerosis	3.04e-06	5.04e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—APOA1—atherosclerosis	3.03e-06	5.02e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PIK3CG—atherosclerosis	2.77e-06	4.59e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PPARG—atherosclerosis	2.67e-06	4.43e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—INS—atherosclerosis	2.62e-06	4.34e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—ALB—atherosclerosis	2.4e-06	3.98e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—NOS3—atherosclerosis	2.3e-06	3.81e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PTGS2—atherosclerosis	2.1e-06	3.48e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—AKT1—atherosclerosis	1.06e-06	1.75e-06	CbGpPWpGaD
